OPK:NSD-Opko Health Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 1.37

Change

+0.03 (+1.86)%

Market Cap

USD 0.98B

Volume

2.25M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-2.65 (-0.50%)

USD 37.95B
NTRA Natera Inc

-1.71 (-1.02%)

USD 20.66B
ILMN Illumina Inc

-0.91 (-1.09%)

USD 11.99B
EXAS EXACT Sciences Corporation

-0.79 (-1.43%)

USD 10.87B
ICLR ICON PLC

-4.79 (-3.43%)

USD 10.35B
MEDP Medpace Holdings Inc

-19.16 (-6.13%)

USD 8.65B
GH Guardant Health Inc

+0.65 (+1.36%)

USD 5.04B
RDNT RadNet Inc

+1.27 (+2.24%)

USD 4.31B
SHC Sotera Health Co

-0.17 (-1.38%)

USD 3.45B
VCYT Veracyte Inc

-0.31 (-1.14%)

USD 2.08B

ETFs Containing OPK

HVAX:CA 5.26 % 0.00 %

N/A

N/A
EMDM First Trust Bloomberg Eme.. 2.94 % 0.00 %

+0.15 (+0.64%)

USD 7.95M
DGRE WisdomTree Emerging Marke.. 1.05 % 0.32 %

+0.13 (+0.64%)

USD 0.14B
QRH:CA 0.00 % 1.20 %

N/A

N/A
IPOL:LSE iShares V Public Limited .. 0.00 % 0.00 %

-0.29 (0.64%)

N/A
SPOL:LSE iShares MSCI Poland UCITS 0.00 % 0.00 %

-25.80 (0.64%)

N/A
EXSD:F iShares STOXX Europe Mid .. 0.00 % 0.00 %

+0.16 (+0.64%)

N/A
IBCJ:F iShares V Public Limited .. 0.00 % 0.00 %

-0.31 (0.64%)

N/A
IBCJ:XETRA iShares MSCI Poland UCITS.. 0.00 % 0.00 %

-0.32 (0.64%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.80% 67% D+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.80% 67% D+ 45% F
Trailing 12 Months  
Capital Gain 2.24% 65% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.24% 63% D 52% F
Trailing 5 Years  
Capital Gain -41.70% 67% D+ 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.70% 63% D 29% F
Average Annual (5 Year Horizon)  
Capital Gain -15.84% 35% F 18% F
Dividend Return -15.84% 35% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.18% 91% A- 54% F
Risk Adjusted Return -47.73% 26% F 17% F
Market Capitalization 0.98B 63% D 72% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector